OrbiMed

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
火曜日, 5月 7, 2024
FDA, VLA, Bank statement, Fast Track, Research, CHMP, Trial of the century, Biologics license application, Coalition, Profit & Loss, OrbiMed, Lyme disease, Bavarian Nordic, CDC, Notifiable disease, Adolescence, Income tax, Chikungunya, Third party, ACIP, BLA, Licensure, CEPI, PRV, Safety, Travel, Indoor Living, EMA, Marketing, USD, Sale, Tropical disease, EDT, Depreciation, MAA, Profit, Euronext Paris, Zika virus, Epidemic, Adjustment, COGS, Saint-Herblain, COVID-19, Growth, Ageing

Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

Key Points: 
  • Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
  • The condensed consolidated interim financial results are available on the Company’s website ( Financial Reports – Valneva ).
  • In the first quarter of 2024, IXIARO®/JESPECT® sales were €16.6 million compared to €17.4 million in the first quarter of 2023.
  • IXIARO®/JESPECT® sales were €16.6 million in the first quarter of 2024 compared to €17.4 million in the first quarter of 2023.

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Retrieved on: 
火曜日, 4月 16, 2024
Sale, Prospectus, Investment, Morgan Stanley, Stifel, SVB Securities, Research, OrbiMed, Exercise, Paradigm, CGEM, Therapy, Security (finance)

CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.001 per share. Cullinan expects to receive gross proceeds from the offering of approximately $280.0 million, before deducting placement agent fees and other offering expenses.

Key Points: 
  • Cullinan expects to receive gross proceeds from the offering of approximately $280.0 million, before deducting placement agent fees and other offering expenses.
  • The private placement is expected to close on or about April 18, 2024, subject to the satisfaction of customary closing conditions.
  • Morgan Stanley, TD Cowen, and Leerink Partners acted as lead placement agents for the private placement.
  • Stifel acted as a placement agent and Wedbush & Co., LLC and BTIG acted as co-placement agents for the private placement.

TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives

Retrieved on: 
火曜日, 4月 30, 2024
Research, Other Health, Professional Services, Pharmaceutical, Oncology, Medical Devices, Clinical Trials, Science, Other Professional Services, Biotechnology, Finance, Health, Other Science, LLP, Covington & Burling, OrbiMed, Therapy, Liver, General partnership, Cooley LLP, Credit, Growth

TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm.

Key Points: 
  • TriSalus Life Sciences Inc., (Nasdaq: TLSI), today announced the closing of a debt financing facility for up to $50 million with OrbiMed, a healthcare investment firm.
  • The capital is expected to provide financial flexibility to support the execution of strategic expansion plans and fuel continued growth.
  • Under the terms of the Credit Agreement (the “Credit Agreement”) with OrbiMed, the Company borrowed $25 million at closing.
  • “We are excited to be partnering with OrbiMed,” said Mary Szela, Chief Executive Officer of TriSalus Life Sciences.

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Retrieved on: 
月曜日, 4月 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis

The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Key Points: 
  • The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
  • Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
  • R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
  • The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.

Edison issues update on The Biotech Growth Trust (BIOG): Onwards and upwards for performance recovery

Retrieved on: 
水曜日, 4月 10, 2024
Prostate cancer, Therapy, OrbiMed, Pharmaceutical industry

The sector was negatively affected by sharply rising interest rates rather than a deterioration in industry fundamentals; indeed, the managers continue to refer to a ‘golden era’ of innovation within the biotech sector.

Key Points: 
  • The sector was negatively affected by sharply rising interest rates rather than a deterioration in industry fundamentals; indeed, the managers continue to refer to a ‘golden era’ of innovation within the biotech sector.
  • BIOG’s relative performance has been through a difficult period given its high weighting in emerging (smaller-cap) biotech stocks, which performed significantly worse than the shares of large-cap biotech businesses during the sector sell-off.
  • BIOG’s managers are very excited about the trust’s prospects and encouraged that investors are once again rewarding biotech companies that deliver positive outcomes.
  • In keeping with many other investment companies, the trust’s discount is wider than its historical averages.

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 4月 3, 2024
DFO, OrbiMed, NESS, Cystic Fibrosis Foundation, APT, FEV1, Part, Phage therapy, Patient, Orphan, KOL, Acquisition, Șaeș, Cystic fibrosis, Infection, Therapy, Pseudomonas aeruginosa, Pharmaceutical industry

CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Initial top line results of the Phase 2 trial are expected in the first quarter of 2025.
  • However, our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
  • ET to discuss its fourth quarter and full year 2023 financial results and to provide a corporate update.

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
火曜日, 4月 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.

Avalo Reports 2023 Financial Results and Provides Business Updates

Retrieved on: 
金曜日, 3月 29, 2024
Exercise, Patient, Research, Acquisition, Inflammation, Net, HS, Therapy, OrbiMed, Hidradenitis suppurativa, Phase II, BTLA, Pharmaceutical industry

Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million

Key Points: 
  • Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million
    WAYNE, Pa. and ROCKVILLE, Md., March 29, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and year-end financial results for 2023.
  • The progress we made in 2023 to strengthen our balance sheet helped enable these transactions.
  • “Our focus in 2024 is executing operationally on the development of AVTX-009 for the treatment of hidradenitis suppurativa.
  • As of December 31, 2023, Avalo had $7.4 million in cash and cash equivalents.

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Retrieved on: 
水曜日, 3月 27, 2024
Eli Lilly, Disease, Half-life, Partnership, Patient, Sale, Acquisition, Inflammation, Therapy, OrbiMed, Hidradenitis suppurativa, Probability, Autoimmune disease

Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027

Key Points: 
  • Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027
    Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T.
  • The private placement will provide up to $185 million in gross proceeds, including an initial gross upfront investment of $115.6 million.
  • After deducting estimated transaction costs from both the private placement financing and the acquisition of AlmataBio, Avalo expects net upfront proceeds to be approximately $105 million.
  • The private placement is expected to close on March 28, 2024, subject to the satisfaction of customary closing conditions.

Nkarta Announces Pricing of $240 Million Underwritten Offering

Retrieved on: 
月曜日, 3月 25, 2024
Janus, SVB Securities, Montgomery Street, Mizuho Securities, 3rd Floor, Telephone, SAN, Research, Sale, Attention, Security (finance), Lexington Avenue, Prospectus, Suite, Annual report, OrbiMed, Equity capital markets, NK, State Street

Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Gross proceeds to Nkarta from this offering are approximately $240.1 million, before deducting underwriting discounts and commissions and offering expenses.
  • The offering is expected to close on or about March 27, 2024, subject to customary closing conditions.
  • All securities in the offering are to be issued and sold by Nkarta.
  • The offering was made only by means of a prospectus supplement and accompanying prospectus describing the terms of the offering.